Bermekimab, a human anti-IL-1α monoclonal antibody, was tested in an RCT (NCT04019041) in 20 patients with moderate-to-severe HS for whom anti-TNF therapy was ineffective or contraindicated. This evidence concerns the gene IL1A and histiocytic sarcoma.